Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge

about

Are We Prepared in Case of a Possible Smallpox-Like Disease Emergence?40 Years without Smallpox.

P2860

Q47116100-C618C176-EC86-4EB6-97AF-9D4220D28FBF Q47552709-241D025D-6B37-409E-96BB-1997DF89BF1B

P2860

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge

Item

http://www.wikidata.org/entity/Q37067250

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Modified Vaccinia Ankara Virus ...... asal Rabbitpox Virus Challenge

@en

Modified Vaccinia Ankara Virus ...... sal Rabbitpox Virus Challenge.

@nl

type

Item

label

Modified Vaccinia Ankara Virus ...... asal Rabbitpox Virus Challenge

@en

Modified Vaccinia Ankara Virus ...... sal Rabbitpox Virus Challenge.

@nl

prefLabel

Modified Vaccinia Ankara Virus ...... asal Rabbitpox Virus Challenge

@en

Modified Vaccinia Ankara Virus ...... sal Rabbitpox Virus Challenge.

@nl

P1476

Modified Vaccinia Ankara Virus ...... asal Rabbitpox Virus Challenge

@en

P2093

Christopher J Sample

http://www.w3.org/2001/XMLSchema#string

David J Pickup

http://www.w3.org/2001/XMLSchema#string

Dorothy I Jones

http://www.w3.org/2001/XMLSchema#string

Herman F Staats

http://www.w3.org/2001/XMLSchema#string

P2860

Stable dry powder formulation for nasal delivery of anthrax vaccine

Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.

Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.

P304

648-651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00216-16

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Charles E McGee

Gregory D Sempowski

P577

2016-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27146001

http://www.w3.org/2001/XMLSchema#string

P932

4933771

http://www.w3.org/2001/XMLSchema#string

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge

about

P2860

P2860

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932